42718-15-0

Basic information

• Product Name: DL-4-Bromophenylglycine
• Synonyms: RS-4-Bromophenylglycine methyl ester
• CAS NO: 42718-15-0
• Molecular Formula: C₉H₁₀BrNO₂
• Molecular Weight: 244.09
• Mol File: 42718-15-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: DL-4-Bromophenylglycine(CAS DataBase Reference)
• NIST Chemistry Reference: DL-4-Bromophenylglycine(42718-15-0)
• EPA Substance Registry System: DL-4-Bromophenylglycine(42718-15-0)

Safety Data

• Hazardous Substances Data: 42718-15-0(Hazardous Substances Data)

Usage

General Description

DL-4-Bromophenylglycine is a chemical compound that belongs to the category of amino acids, specifically a derivative of glycine. It is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs, including antipsychotic and analgesic medications. DL-4-Bromophenylglycine is known for its role in the development of novel therapeutic agents due to its ability to modulate neurotransmitter activity in the central nervous system. Additionally, DL-4-Bromophenylglycine has been studied for its potential anti-inflammatory and anticonvulsant properties, making it a versatile and valuable chemical in medical research and drug development.

Upstream product

• 67-56-1 methanol 
• 119397-06-7 2-amino-2-(4-bromophenyl)acetic acid 

Downstream Products

• 383363-37-9 N-(4-bromophenylglycine methyl ester)-3,5-dichloro-4-pyridinyl carboxamide 
• 709665-73-6 methyl 2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)acetate 
• 369403-44-1 2-([1,1'-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)acetic acid 

Relevant articles and documents

Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases

There is an urgent clinical need for antimalarial compounds that target malaria caused by both Plasmodium falciparum and Plasmodium vivax. The M1 and M17 metalloexopeptidases play key roles in Plasmodium hemoglobin digestion and are validated drug targets. We used a multitarget strategy to rationally design inhibitors capable of potent inhibition of the M1 and M17 aminopeptidases from both P. falciparum (Pf-M1 and Pf-M17) and P. vivax (Pv-M1 and Pv-M17). The novel chemical series contains a hydroxamic acid zinc binding group to coordinate catalytic zinc ion/s, and a variety of hydrophobic groups to probe the S1′ pockets of the four target enzymes. Structural characterization by cocrystallization showed that selected compounds utilize new and unexpected binding modes; most notably, compounds substituted with bulky hydrophobic substituents displace the Pf-M17 catalytic zinc ion. Excitingly, key compounds of the series potently inhibit all four molecular targets and show antimalarial activity comparable to current clinical candidates.

NOVEL AMINOPEPTIDASE INHIBITORS AND METHODS OF USE

An aminopeptidase inhibitor compound comprising a biaryl, hydroxamic acid based core of formula: wherein X is a 5 or 6-membered ring, and including pharmaceutically acceptable salts and solvates thereof.

AMIDE DERIVATIVES AS KINASE INHIBITORS

The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula (I) or (II) or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, or solvate thereof, wherein Ar1, Ar2, R1, R3, p and n have the meaning defined in the claims. In particular, the present invention relates to more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.